FFCP PHASE1:Mm9::chr17:70883915..70883925,+: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{FFCP|EntrezGene=NA|HGNC=|MCL_coexpression_id=6|UniProt=NA|association_with_transcript=NA|description=CAGE_peak_at_chr17:70883915..70883925,+|id=chr17:70883915..70883925,+|ontology_enrichment_celltype=|ontology_enrichment_celltype_v019_2=CL:0000355,4.50e-18,9|ontology_enrichment_disease=DOID:0060100!5.59e-15!3;DOID:4045!5.59e-15!3;DOID:0050686!1.01e-07!6|ontology_enrichment_disease_v019_2=DOID:0060100,3.69e-52,3;DOID:4045,3.69e-52,3;DOID:0050686,1.27e-26,6|ontology_enrichment_uberon=|ontology_enrichment_uberon_v019_2=UBERON:0001134,4.50e-18,9;UBERON:0002036,4.50e-18,9;UBERON:0002385,4.50e-18,9;UBERON:0000486,4.50e-18,9;UBERON:0007503,4.50e-18,9;UBERON:0001015,4.50e-18,9;UBERON:0002329,4.50e-18,9;UBERON:0003082,4.50e-18,9;UBERON:0003059,4.50e-18,9;UBERON:0007282,4.50e-18,9;UBERON:0004290,4.50e-18,9;UBERON:0009618,4.50e-18,9;UBERON:0000383,2.34e-16,10;UBERON:0007524,5.95e-15,11;UBERON:0003077,5.95e-15,11;UBERON:0007285,5.95e-15,11|phase1_expression=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3.34825304589526,1.5626706890476,1.57057123192139,21.1763335691165,2.73218193983378,0.971020706062307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.255715457330331,0,0,0,0.248813941220186,0,0,0,0,0.180062129805349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.284163499395593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.22237804384487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.763877555344259,0.287696137450811,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.117211686592203,0,0,0,0,0,0,0,0,0,0,0,0.321321316421807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.370389054739423,0.188368457004691,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.13020438484395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.171853182343688,0,0,0,0,0.453142408984205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0|short_description=p@chr17:70883915..70883925,+}} | {{FFCP | ||
|DHSsupport=NA | |||
|DPIdataset=NA | |||
|EntrezGene=NA | |||
|HGNC= | |||
|MCL_coexpression_id=6 | |||
|TSSclassifier=NA | |||
|UniProt=NA | |||
|association_with_transcript=NA | |||
|cluster_id=chr17:70883915..70883925,+ | |||
|description=CAGE_peak_at_chr17:70883915..70883925,+ | |||
|id=chr17:70883915..70883925,+ | |||
|ontology_enrichment_celltype= | |||
|ontology_enrichment_celltype_v019_2=CL:0000355,4.50e-18,9 | |||
|ontology_enrichment_disease=DOID:0060100!5.59e-15!3;DOID:4045!5.59e-15!3;DOID:0050686!1.01e-07!6 | |||
|ontology_enrichment_disease_v019_2=DOID:0060100,3.69e-52,3;DOID:4045,3.69e-52,3;DOID:0050686,1.27e-26,6 | |||
|ontology_enrichment_uberon= | |||
|ontology_enrichment_uberon_v019_2=UBERON:0001134,4.50e-18,9;UBERON:0002036,4.50e-18,9;UBERON:0002385,4.50e-18,9;UBERON:0000486,4.50e-18,9;UBERON:0007503,4.50e-18,9;UBERON:0001015,4.50e-18,9;UBERON:0002329,4.50e-18,9;UBERON:0003082,4.50e-18,9;UBERON:0003059,4.50e-18,9;UBERON:0007282,4.50e-18,9;UBERON:0004290,4.50e-18,9;UBERON:0009618,4.50e-18,9;UBERON:0000383,2.34e-16,10;UBERON:0007524,5.95e-15,11;UBERON:0003077,5.95e-15,11;UBERON:0007285,5.95e-15,11 | |||
|phase1_expression=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3.34825304589526,1.5626706890476,1.57057123192139,21.1763335691165,2.73218193983378,0.971020706062307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.255715457330331,0,0,0,0.248813941220186,0,0,0,0,0.180062129805349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.284163499395593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.22237804384487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.763877555344259,0.287696137450811,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.117211686592203,0,0,0,0,0,0,0,0,0,0,0,0.321321316421807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.370389054739423,0.188368457004691,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.13020438484395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.171853182343688,0,0,0,0,0.453142408984205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 | |||
|short_description=p@chr17:70883915..70883925,+ | |||
}} |
Latest revision as of 06:44, 5 August 2015
Short description: | p@chr17:70883915..70883925, + |
---|---|
Species: | Mouse (Mus musculus) |
DPI dataset: | NA |
TSS-like-by-RIKEN-classifier(Yes/No): | NA |
DHS support(Yes/No): | NA |
Description: | CAGE_peak_at_chr17:70883915..70883925, + |
Coexpression cluster: | MCL_coexpression_mm9:6 |
Association with transcript: | NA |
EntrezGene: | NA |
Link to Zenbu: | ZENBU |
View on UCSC genome browser
CAGE Expression
- Click each plot point to find sample in table
Ontology-based sample term enrichment analysis<b>Summary:</b>This analysis has been performed by utilizing wilcoxon rank sum test.When the number of associated cells/tissues are > n , randomly sampled n cells/tissues are used for P value calculation with rank sum test. this process are repeated several times, and the P values are averaged on the log space <br><b>Analyst:</b> Hideya Kawaji<br><br>link to source dataset<br>data
Ontology term | p-value | n |
---|---|---|
multi-potent skeletal muscle stem cell | 4.50e-18 | 9 |
Ontology term | p-value | n |
---|---|---|
skeletal muscle tissue | 4.50e-18 | 9 |
striated muscle tissue | 4.50e-18 | 9 |
muscle tissue | 4.50e-18 | 9 |
multilaminar epithelium | 4.50e-18 | 9 |
epithelial vesicle | 4.50e-18 | 9 |
musculature | 4.50e-18 | 9 |
somite | 4.50e-18 | 9 |
myotome | 4.50e-18 | 9 |
presomitic mesoderm | 4.50e-18 | 9 |
presumptive segmental plate | 4.50e-18 | 9 |
dermomyotome | 4.50e-18 | 9 |
trunk paraxial mesoderm | 4.50e-18 | 9 |
musculature of body | 2.34e-16 | 10 |
dense mesenchyme tissue | 5.95e-15 | 11 |
paraxial mesoderm | 5.95e-15 | 11 |
presumptive paraxial mesoderm | 5.95e-15 | 11 |
Ontology term | p-value | n |
---|---|---|
musculoskeletal system cancer | 3.69e-52 | 3 |
muscle cancer | 3.69e-52 | 3 |
organ system cancer | 1.27e-26 | 6 |